Anlotinib Retrospective Study for Esophageal Cancer

Efficacy and Safety of Anlotinib in the First-line or Second-line Treatment of Locally Advanced or Metastatic Esophageal Cancer in China, a Retrospective, Multicenter, Real-world Study

The efficacy of anlotinib in the treatment of esophageal cancer has been confirmed. The purpose of this study was to retrospectively observe the efficacy and safety of anlotinib in the first and second line of advanced esophageal cancer in the real world.

Inclusion Criteria:

• Esophageal cancer diagnosed pathologically or clinically
• Patients who use anlotinib alone, or combined with chemoradiotherapy, or plus PD-1 inhibitors in first-line or second-line treatment

Exclusion Criteria:

None